Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: STA-9090
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Synta Pharmaceuticals Corp.